Sector News

Aptuit announces acquisition of Exquiron Biotech AG

April 25, 2016
Life sciences

Aptuit, LLC today announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.

Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.

Dr. Jonathan Goldman, Chief Executive Officer of Aptuit stated, “Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery. In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.

Customers value our unique capabilities in integrated discovery and integrated development. We are delighted to combine our core scientific expertise in discovery with the early discovery capabilities of our Exquiron colleagues.”

Dr. Goldman explained that Aptuit’s best in class integrated discovery solutions are unique in the marketplace.

“Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities”.

Dr. Stephan Fasler, CEO and founder of Exquiron added, “We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit”

Source: Aptuit

comments closed

Related News

March 25, 2023

UK regulator makes biggest changes in 20 years to speed up trials, attract global studies

Life sciences

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.

March 25, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

Life sciences

Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.

March 25, 2023

Sanofi’s Dupixent receives EC approval for atopic dermatitis

Life sciences

Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.

How can we help you?

We're easy to reach